1 Market Overview
1.1 Product Overview and Scope of HER-2 Targeted Drugs for Breast Cancer
1.2 Classification of HER-2 Targeted Drugs for Breast Cancer by Type
1.2.1 Overview: Global HER-2 Targeted Drugs for Breast Cancer Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Type in 2020
1.2.3 Trastuzumab
1.2.4 Pertuzumab
1.2.5 Lapatinib
1.2.6 Neratinib
1.2.7 Trastuzumab Emtansine
1.2.8 Pyrotinib
1.2.9 Other
1.3 Global HER-2 Targeted Drugs for Breast Cancer Market by Application
1.3.1 Overview: Global HER-2 Targeted Drugs for Breast Cancer Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Other
1.4 Global HER-2 Targeted Drugs for Breast Cancer Market Size & Forecast
1.5 Global HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast by Region
1.5.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global HER-2 Targeted Drugs for Breast Cancer Market Size by Region, (2016-2021)
1.5.3 North America HER-2 Targeted Drugs for Breast Cancer Market Size and Prospect (2016-2026)
1.5.4 Europe HER-2 Targeted Drugs for Breast Cancer Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size and Prospect (2016-2026)
1.5.6 South America HER-2 Targeted Drugs for Breast Cancer Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa HER-2 Targeted Drugs for Breast Cancer Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 HER-2 Targeted Drugs for Breast Cancer Market Drivers
1.6.2 HER-2 Targeted Drugs for Breast Cancer Market Restraints
1.6.3 HER-2 Targeted Drugs for Breast Cancer Trends Analysis
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.1.4 Roche HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Roche Recent Developments and Future Plans
2.2 Chugai Pharmaceutical
2.2.1 Chugai Pharmaceutical Details
2.2.2 Chugai Pharmaceutical Major Business
2.2.3 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.2.4 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Chugai Pharmaceutical Recent Developments and Future Plans
2.3 GlaxoSmithKline
2.3.1 GlaxoSmithKline Details
2.3.2 GlaxoSmithKline Major Business
2.3.3 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.3.4 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 GlaxoSmithKline Recent Developments and Future Plans
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.4.4 Novartis HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Novartis Recent Developments and Future Plans
2.5 Pfizer
2.5.1 Pfizer Details
2.5.2 Pfizer Major Business
2.5.3 Pfizer HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.5.4 Pfizer HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Pfizer Recent Developments and Future Plans
2.6 CANbridge
2.6.1 CANbridge Details
2.6.2 CANbridge Major Business
2.6.3 CANbridge HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.6.4 CANbridge HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 CANbridge Recent Developments and Future Plans
2.7 Puma Biotechnology
2.7.1 Puma Biotechnology Details
2.7.2 Puma Biotechnology Major Business
2.7.3 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.7.4 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Puma Biotechnology Recent Developments and Future Plans
2.8 Hengrui Medicine
2.8.1 Hengrui Medicine Details
2.8.2 Hengrui Medicine Major Business
2.8.3 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.8.4 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Hengrui Medicine Recent Developments and Future Plans
2.9 Beacon Pharmaceuticals Limited
2.9.1 Beacon Pharmaceuticals Limited Details
2.9.2 Beacon Pharmaceuticals Limited Major Business
2.9.3 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.9.4 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Beacon Pharmaceuticals Limited Recent Developments and Future Plans
2.10 Hetero Drugs
2.10.1 Hetero Drugs Details
2.10.2 Hetero Drugs Major Business
2.10.3 Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Product and Solutions
2.10.4 Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Hetero Drugs Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global HER-2 Targeted Drugs for Breast Cancer Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 HER-2 Targeted Drugs for Breast Cancer Players Market Share
3.2.2 Top 10 HER-2 Targeted Drugs for Breast Cancer Players Market Share
3.2.3 Market Competition Trend
3.3 HER-2 Targeted Drugs for Breast Cancer Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global HER-2 Targeted Drugs for Breast Cancer Revenue and Market Share by Type (2016-2021)
4.2 Global HER-2 Targeted Drugs for Breast Cancer Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global HER-2 Targeted Drugs for Breast Cancer Revenue Market Share by Application (2016-2021)
5.2 HER-2 Targeted Drugs for Breast Cancer Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2016-2026)
6.2 North America HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2016-2026)
6.3 North America HER-2 Targeted Drugs for Breast Cancer Market Size by Country
6.3.1 North America HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2016-2026)
6.3.2 United States HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
6.3.3 Canada HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
6.3.4 Mexico HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2016-2026)
7.2 Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2016-2026)
7.3 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Country
7.3.1 Europe HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2016-2026)
7.3.2 Germany HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
7.3.3 France HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
7.3.4 United Kingdom HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
7.3.5 Russia HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
7.3.6 Italy HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2016-2026)
8.2 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2016-2026)
8.3 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Region
8.3.1 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Revenue by Region (2016-2026)
8.3.2 China HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
8.3.3 Japan HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
8.3.4 South Korea HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
8.3.5 India HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
8.3.7 Australia HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2016-2026)
9.2 South America HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2016-2026)
9.3 South America HER-2 Targeted Drugs for Breast Cancer Market Size by Country
9.3.1 South America HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2016-2026)
9.3.2 Brazil HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
9.3.3 Argentina HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Type (2016-2026)
10.2 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Application (2016-2026)
10.3 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Country
10.3.1 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Revenue by Country (2016-2026)
10.3.2 Turkey HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
10.3.4 UAE HER-2 Targeted Drugs for Breast Cancer Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
【掲載企業】
Roche、Chugai Pharmaceutical、GlaxoSmithKline、Novartis、Pfizer、CANbridge、Puma Biotechnology、Hengrui Medicine、Beacon Pharmaceuticals Limited、Hetero Drugs
【免責事項】
https://www.globalresearch.jp/disclaimer